PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ajcrLink to Publisher's site
 
Am J Cancer Res. 2012; 2(3): 335–339.
Published online Apr 21, 2012.
PMCID: PMC3365804
Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach
Oluwole Fadare1,2 and Wenxin Zheng3,4,5,6
1Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN
2Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, TN
3Department of Pathology, University of Arizona College of Medicine, Tucson, AZ
4Department of Obstetrics and Gynecology, University of Arizona, Tucson, AZ
5Arizona Cancer Center, University of Arizona, Tucson, AZ
6Department of Obstetrics and Gynecology, Shandong University, China
Address correspondence to: Dr. Wenxin Zheng, Professor of Pathology, Professor of Obstetrics and Gynecology, University of Arizona College of Medicine, 1501 N Campbell Ave, Tucson, AZ 85724 E-mail: zhengw/at/email.arizona.edu
Received April 4, 2012; Accepted April 17, 2012.
Uterine corpus cancers, the vast majority of which are endometrial carcinomas, are diagnosed in approximately 47,130 women every year in the United States, which makes them the most frequently diagnosed malignancy of the gynecologic tract, and the 4th most commonly diagnosed malignancy in women overall [1]. The vast majority of endometrial carcinomas are of the endometrioid histotype, are localized to the uterus at presentation, and accordingly have a good prognosis [2]. Endometrial serous carcinomas (ESC), also known as uterine papillary serous carcinomas, represent about 10% of endometrial carcinomas, and have traditionally been conceptualized as being a clinically aggressive histotype [3,4] since they are responsible for up to 40% of all deaths and recurrences associated with endometrial cancer [5]. At the clinical level, this aggressiveness is related, at least partially, to the comparatively higher stage at which ESC patients present [2]. For example, amongst the endometrial cancers reported to the International Federation of Gynecology and Obstetrics for the 1999-2001 period, only 1021 (13.9%) of the 7333 endometrioid cancers were late stage, as compared with 143 (41.3%) of 346 ESCs [2]. At least 37% of ESC cases that display no invasion in the uterus are found to have stage III or IV disease after comprehensive surgical staging, which highlights the significance of the latter procedure in accurately defining the extent of disease for patients with this cancer [6]. However, for patients that truly have uterine corpus-confined disease after surgical staging, and certainly those with stage IA, non-myoinvasive or minimally-invasive disease, the reported outcomes have been good to excellent [7-15], although the optimal adjuvant management for these patients remains a matter of debate [16,17]. For patients with stage III or IV disease, reported outcomes have generally been dismal, irrespective of adjuvant therapeutic modalities [18,19]. These findings highlight the importance of intercepting the disease at an early stage, and possibly applying an ablative intervention before its development [20,21].
The concept of an intraepithelial, non-invasive, and possibly precancerous phase of ESC has been recognized for nearly two decades. This lesion has variably been designated as “endometrial intraepithelial carcinoma” (EIC), “serous EIC”, “uterine surface carcinoma”, “endometrial carcinoma in situ” and “minimal serous carcinoma” [22-27]. This lesion is characterized by the colonization and replacement of benign surface endometrium and glands by cells that are cytologically identical to serous carcinoma, is frequently multifocal, is seen in association with up to 89% of ESC cases, and was postulated to represent the precursor lesion to ESC for many years [28]. It has also long been recognized, however, that a significant subset (up to two-thirds) of patients with pure serous EIC (and no ESC as conventionally defined) may have extrauterine disease of the same morphology, immunophenotype, and molecular features [29-32]. The specific biologic properties of carcinomas with the serous phenotype (possibly related to alterations in cell adhesion molecules) confers upon them the ability to disseminate even in the absence of a morphologically apparent invasive growth. Therefore, as a practical matter, although serous EIC may represent a non-invasive appearing growth pattern of ESC, it has the same clinical implications as the latter, and cannot be considered a precancerous lesion for the purposes of prevention. This recognition is reflected in the patient management recommendations for serous EIC, which largely mirror those for early stage conventional ESC, and include total hysterectomy, bilateral salpingo-oophorectomy, pelvic and periaortic lymph node dissections, multiple peritoneal biopsies and omentectomy, with the need for adjuvant chemotherapy being dependent on the resultant findings [32].
Studies from our group over the past decade have defined a lesion that we consider to be a more likely preccancer for ESC, and which we have designated as “Endometrial glandular dysplasia” (EmGD) [33-38]. In one study, this lesion was identified in approximately half (53%) the “benign” endometria adjacent to the conventional ESC cases that were examined, as compared with 1.7% of the endometrioid cancers [34]. The typical EmGD focus shows epithelial segments (surface epithelium or isolated single cells) lined by cells with nucleomegaly (2-4 times resting endometrium, as compared with 4-5 times in serous EIC), appreciable but non-conspicuous nucleoli, variable hyperchromasia, loss of nuclear polarity, and generally stand out from the background endometrium in which they are identified. They are multifocal in up to 86% of patients, but each focus is usually less than 1 mm [20]. We have recently outlined the evidentiary basis for the consideration of EmGD as the precancerous lesion for ESC in a recent authoritative review article [20]. EmGD fulfils the National Cancer Institute criteria for a precancerous lesion [39], as briefly summarized below. The first criterion calls for the putative precancerous lesion to be distinct from the normal tissue from which it arose. As outlined above, EmGD fulfils this criterion. The second criterion calls for the putative precancer to share some, but not all molecular and phenotypic properties of the cancerous lesion. As we have detailed elsewhere, when the TP53 mutational load between ESC (including serous EIC) and EmGD were compared, it is clearly greater in the former [20]. At the morphologic level, by definition, ESC/EIC displays greater anaplasia than EmGD. At the phenotypic level, insulin-like growth factor II mRNA-binding protein 3 (IMP3), a protein that is highly expressed in ESC, shows a significantly lower expression level in EmGD as compared with ESC [36]. The third criterion that must be fulfilled is that when a precancer progresses to cancer, the resulting cancer must arise from cells within the precancer. Our analysis of TP53 gene mutations (exons 5-8) in 6 uteri with EmGD and ESC identified at least 1 identical mutation in all six [20]. HUMARA assays have also identified identical allele losses in synchronous lesions of EmGD, serous EIC and ESC in up to 75% of cases [20]. The fourth criterion is that there is a method by which the precancerous lesion can be diagnosed (see diagnostic morphologic features above). The fifth and final criterion is that the precancerous lesion increases the risk for cancer. On the latter point, there is only one retrospective study available, in which the “benign” biopsies that preceded the diagnosis of ESC were re-evaluated and lesions meeting the diagnostic criteria for EmGD were re-analysed [35]. On the basis of this study, it was estimated that the diagnosis of EmGD in an endometrial biopsy may confer up to a 9-fold increased risk for developing ESC, although it is readily acknowledged that additional research is warranted to truly define the natural history of the lesion [35]. Accordingly, based on the totality of these clinicopathologic findings, EmGD is the most likely candidate precancer for ESC at present time.
A variety of molecular alterations have been described in ESC. The primary molecular event involves mutations in the TP53 tumor suppressor gene, which appears to be an early event in serous carcinogenesis and a frequent, near-uniform event in the established malignancy. TP53 gene mutations occur in 22.7 to 96% of ESC, and p53 protein overexpression is seen in approximately 76%-90% [21]. Morphologically normal endometrial cells adjacent to ESC have been found to occasionally display strong p53 expression as assessed by immunohistochemistry, and these foci have been designated as “p53 signatures” [38,40]. P53 signatures have a significantly stronger association with serous, as compared with endometrioid carcinomas, and have a frequency of TP53 gene mutation that is comparable to EmGD, but significantly less than serous EIC/ESC (38). Furthermore, occasional cases show identical TP53 mutations in all 3 lesions (p53 signatures, EmGD, serous EIC/ESC). These, and other findings formed the basis for a model of endometrial serous carcinogenesis that we have recently proposed, in which a sequence of lesions appear through the progressive accumulation of molecular aberrations: resting endometrium→ p53 signatures→EmGD→serous EIC→ESC [20]. Other noteworthy molecular and phenotypic aberrations that have been described in ESC include genetic instability, the upregulation of p16 and the probable dysregulation of both the p16(INKA)/Cyclin D-CDK/pRb-E2F and the ARF-MDM2-p53 cell cycle pathways, HER2/neu amplification, PIK3CA mutations, overexpression of IMP3, EGFR, HMGA2 and Nrf2, the loss of expression of CD44 and the estrogen and progesterone receptors, evidence of epithelial-to-mesenchymal transformation, and alterations in the expression of celladhesion molecules [20,21,41-47]. As previously noted, TP53 mutations appear to be the central and earliest molecular events in endometrial serous carcinogenesis [20,21].
As is true with many cancers, a significant reduction in patient mortality can be achieved by the diagnosis and treatment of the disease at an early stage once it develops, or prevention of the disease from developing in the first place. The accurate diagnosis and treatment of the precursor lesions for ESC is one preventive approach that may ultimately reduce the incidence and mortality of this disease. At present, irrespective of whether a patient is at the EmGD, serous EIC or ESC phase of their disease, an endometrial biopsy needs to be performed, usually due to the patient’s presentation with abnormal uterine bleeding or abnormal glandular cells found on Pap smears. Unfortunately, there are presently no non-invasive screening methods that have been shown to be effective for endometrial carcinomas in general. Given the central role that TP53 mutations play in endometrial serous carcinogenesis, one possibility, which we are currently in the process of evaluating, is the utility of serum anti-p53 antibodies in this setting. In lung and head and neck cancers, there are reports that not only variably ascribe some prognostic value to the assessment of these antibodies, but also suggest that anti-p53 antibodies may be seen in the subclinical phase of cancer development [48-51]. It would therefore be of tremendous interest to investigate how early anti-p53 antibodies are detectable in the process of ESC-development, and whether their measurement will provide the requisite level of sensitivity and specificity for clinical use, including the stratification of patients with a biopsy diagnosis of EmGD regarding their risk of a concurrent more serious lesion. Large scale, multi-institutional studies are urgently needed to prospectively define the outcomes in patients that are diagnosed with a serous precancer (or a lesion that is suspicious for a precancer) in an endometrial biopsy. Evidence-based patient management guidelines can then be formulated and uniformly applied. Meanwhile, we can only hope that with continued research and resultant clarification of these issues, the promise of a preventive approach will move out of the theoretical realm into the practical one.
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. [PubMed]
2. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003;83:79–118. [PubMed]
3. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108. [PubMed]
4. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004;11:117–142. [PubMed]
5. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22:21–29. [PubMed]
6. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463–469. [PubMed]
7. Gallion HH, van Nagell JR Jr, Powell DF, Donaldson ES, Higgins RV, Kryscio RJ, Pavlik EJ, Nelson K. Stage I serous papillary carcinoma of the endometrium. Cancer. 1989;63:2224–2228. [PubMed]
8. Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol. 2001;81:279–286. [PubMed]
9. Huh WK, Powell M, Leath III CA, Straughn JM Jr, Cohn DE, Gold MA, Falkner CA, Carey DE, Herzog T, Fowler JM, Partridge EE, Kilgore LC, Alvarez RD. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecologic Oncology. 2003;91:470–475. [PubMed]
10. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47:298–305. [PubMed]
11. Grice J, Ek M, Greer B, Koh WJ, Muntz HG, Cain J, Tamimi H, Stelzer K, Figge D, Goff BA. Uterine papillary serous carcinoma: evaluation of longterm survival in surgically staged patients. Gynecol Oncol. 1998;69:69–73. [PubMed]
12. Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O'Malley DM, Tuller ER, Rose PG, Havrilesky LJ, Moore KN, Huh WK, Axtell AE, Kelley JL, Zanotti KM. UPSC Consortium. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC) Gynecologic Oncology. 2009;115:244–248. [PubMed]
13. Havrilesky LJ, Alvarez Secord A, Bae-Jump V, Ayeni T, Calingaert B, Clarke-Pearson DL, Berchuck A, Gehrig PA. Outcomes in surgical stage 1 uterine papillary serous carcinoma. Gynecologic Oncology. 2007;105:677–682. [PubMed]
14. Kelly MG, O’Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecologic Oncology. 2005;98:353–359. [PubMed]
15. Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV, Ueda SM, Fleury AC, Diaz-Montes TP, Bristow RE. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer. 2012;22:273–279. [PubMed]
16. Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142–153. [PubMed]
17. Elit L, Laroche A, Smith L, Mazurka J, Moens F, Hauspy J, Jimenez W. Management of women with surgically staged 1 uterine papillary serous cancer. ISRN Obstet Gynecol. 2011;2011:146264. [PMC free article] [PubMed]
18. Growdon WB, Rauh-Hain JJ, Cordon A, Garrett L, Schorge JO, Goodman A, Boruta DM, Horowitz NS, del Carmen MG. Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer. 2012;22:417–424. [PubMed]
19. Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2003;57:208–216. [PubMed]
20. Zheng W, Xiang L, Fadare O, Kong B. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol. 2011;35:e1–e14. [PubMed]
21. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol. 2009;2:411–432. [PMC free article] [PubMed]
22. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16:600–10. [PubMed]
23. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260–1267. [PubMed]
24. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol. 1995;19:417–432. [PubMed]
25. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol. 1998;22:1463–1473. [PubMed]
26. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797–806. [PubMed]
27. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Lyon: IARC Press; 2003. Pathology and Genetics of Tumours of the Breast and Female Genital Organs.
28. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295–308. [PubMed]
29. Soslow RA, Pirog E, Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol. 2000;24:726–732. [PubMed]
30. Baergen RN, Warren CD, Isacson C, Ellenson LH. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol. 2001;20:214–219. [PubMed]
31. Yan Z, Hui P. Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases. Appl Immunohistochem Mol Morphol. 2010;18:75–79. [PubMed]
32. Zheng W, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol. 2005;96:579–582. [PubMed]
33. Liang SX, Chambers SK, Cheng L, Zhang S, Zhou Y, Zheng W. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol. 2004;12:319–331. [PubMed]
34. Zheng W, Liang SX, Yu H, Rutherford T, Chambers SK, Schwartz PE. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol. 2004;12:207–223. [PubMed]
35. Zheng W, Liang SX, Yi X, Ulukus EC, Davis JR, Chambers SK. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol. 2007;26:38–52. [PubMed]
36. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304–315. [PubMed]
37. Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, Zheng W. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14:2263–2269. [PubMed]
38. Zhang X, Liang SX, Jia L, Chen N, Fadare O, Schwartz PE, Kong B, Zheng W. Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol. 2009;174:2000–2006. [PubMed]
39. Berman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, Hruban RH, Mutter GL, Page D, Rohan T, Travis W, Henson DE. Precancer: a conceptual working definition - - results of a Consensus Conference. Cancer Detect Prev. 2006;30:387–394. [PubMed]
40. Jarboe EA, Pizer ES, Miron A, Monte N, Mutter GL, Crum CP. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol. 2009;22:345–350. [PMC free article] [PubMed]
41. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol. 2009;113:370–373. [PMC free article] [PubMed]
42. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8:1271–1279. [PubMed]
43. Chen N, Yi X, Abushahin N, Pang S, Zhang D, Kong B, Zheng W. Nrf2 expression in endometrial serous carcinomas and its precancers. Int J Clin Exp Pathol. 2010;4:85–96. [PMC free article] [PubMed]
44. Santin AD, Zhan F, Cane S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J Jr, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer. 2005;92:1561–1573. [PMC free article] [PubMed]
45. Hosford S, Elliott J, Ma ZW, Majeste R, Dubeshter B. CD44 expression in papillary serous endometrial carcinoma. Int J Gynecol Cancer. 2003;13:480–484. [PubMed]
46. McCluggage WG, Connolly LE, McBride HA, Kalloger S, Gilks CB. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology. 2012;60:547–553. [PubMed]
47. Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008;21:912–23. [PubMed]
48. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F, Soussi T. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1228–1233. [PubMed]
49. Laudanski J, Burzykowski T, Niklinska W, Chyczewski K, Furman M, Niklinski J. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer. 1998;22:191–200. [PubMed]
50. Lai CL, Tsai CM, Tsai TT, Kuo BI, Chang KT, Fu HT, Perng RP, Chen JY. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res. 1998;4:3025–3030. [PubMed]
51. Lutz W, Nowakowska-Swirta E. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process. Int J Occup Med Environ Health. 2002;15:209–218. [PubMed]
Articles from American Journal of Cancer Research are provided here courtesy of
e-Century Publishing Corporation